JP6165627B2 - Ｈｌａの適合なしに造血機能を提供するための組成物および方法 - Google Patents

Ｈｌａの適合なしに造血機能を提供するための組成物および方法 Download PDF

Info

Publication number
JP6165627B2
JP6165627B2 JP2013504018A JP2013504018A JP6165627B2 JP 6165627 B2 JP6165627 B2 JP 6165627B2 JP 2013504018 A JP2013504018 A JP 2013504018A JP 2013504018 A JP2013504018 A JP 2013504018A JP 6165627 B2 JP6165627 B2 JP 6165627B2
Authority
JP
Japan
Prior art keywords
cells
cord blood
cell
umbilical cord
proliferating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013504018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523841A (ja
JP2013523841A5 (enExample
Inventor
バーンスタイン，アーウィン，デー．
デラニー，コリーン
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター, フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2013523841A publication Critical patent/JP2013523841A/ja
Publication of JP2013523841A5 publication Critical patent/JP2013523841A5/ja
Application granted granted Critical
Publication of JP6165627B2 publication Critical patent/JP6165627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013504018A 2010-04-09 2011-04-11 Ｈｌａの適合なしに造血機能を提供するための組成物および方法 Active JP6165627B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32254410P 2010-04-09 2010-04-09
US61/322,544 2010-04-09
PCT/US2011/031953 WO2011127470A1 (en) 2010-04-09 2011-04-11 Compositions and methods for providing hematopoietic function without hla matching

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017056141A Division JP6853081B2 (ja) 2010-04-09 2017-03-22 Ｈｌａの適合なしに造血機能を提供するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013523841A JP2013523841A (ja) 2013-06-17
JP2013523841A5 JP2013523841A5 (enExample) 2015-05-21
JP6165627B2 true JP6165627B2 (ja) 2017-07-19

Family

ID=44120970

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013504018A Active JP6165627B2 (ja) 2010-04-09 2011-04-11 Ｈｌａの適合なしに造血機能を提供するための組成物および方法
JP2017056141A Active JP6853081B2 (ja) 2010-04-09 2017-03-22 Ｈｌａの適合なしに造血機能を提供するための組成物および方法
JP2019051186A Active JP6998911B2 (ja) 2010-04-09 2019-03-19 Ｈｌａの適合なしに造血機能を提供するための組成物
JP2021066078A Pending JP2021105045A (ja) 2010-04-09 2021-04-08 Ｈｌａの適合なしに造血機能を提供するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017056141A Active JP6853081B2 (ja) 2010-04-09 2017-03-22 Ｈｌａの適合なしに造血機能を提供するための組成物および方法
JP2019051186A Active JP6998911B2 (ja) 2010-04-09 2019-03-19 Ｈｌａの適合なしに造血機能を提供するための組成物
JP2021066078A Pending JP2021105045A (ja) 2010-04-09 2021-04-08 Ｈｌａの適合なしに造血機能を提供するための組成物および方法

Country Status (5)

Country Link
US (4) US20130095079A1 (enExample)
EP (3) EP3097917B1 (enExample)
JP (4) JP6165627B2 (enExample)
CA (1) CA2795627C (enExample)
WO (1) WO2011127470A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3741842A4 (en) * 2018-09-27 2021-04-21 TERUMO Kabushiki Kaisha CELL CRYOPRESERVATION METHOD

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203081A1 (en) 2011-12-08 2015-10-16 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
CA2897499A1 (en) 2013-01-08 2014-07-17 Fred Hutchinson Cancer Research Center Compositions and methods for expansion of embryonic hematopoietic stem cells
NZ758715A (en) * 2013-10-31 2023-01-27 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2015120197A1 (en) * 2014-02-05 2015-08-13 Regents Of The University Of California Rna editing biomarkers for diagnosis, pharmacological screening and prognostication in cancer
FR3026744B1 (fr) 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
WO2016076428A1 (ja) * 2014-11-14 2016-05-19 日本赤十字社 臍帯血および末梢血の凍結保存方法および凍結保存用溶液
JP2016104711A (ja) * 2014-11-21 2016-06-09 国立大学法人 東京大学 造血幹細胞移植を補助することに用いるための医薬組成物およびその製造方法
US10350245B2 (en) 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
WO2016151476A1 (en) * 2015-03-23 2016-09-29 Pluristem Ltd. Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof
WO2016176651A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
CN108473949A (zh) * 2015-12-04 2018-08-31 弗莱德哈钦森癌症研究中心 扩增的造血干细胞/祖细胞群体的用途
CA3053294A1 (en) 2017-02-13 2018-08-16 Assistance Publique - Hopitaux De Paris Method for generating t cells progenitors
CN110621321B (zh) 2017-03-15 2024-06-21 浩康生物系统公司 用于造血干细胞移植的组合物和方法
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
KR20220020277A (ko) * 2019-05-17 2022-02-18 데베라 테라퓨틱스 인크. 확장된 줄기 세포 생성물을 사용하여 혈액 악성종양을 갖는 환자에 대한 치료 결과를 개선시키기 위한 조성물 및 방법
WO2021021963A1 (en) * 2019-07-29 2021-02-04 Deverra Therapeutics Inc. Nk cell composition and preparations for immunotherapy and methods for their production
JP2023503982A (ja) * 2019-11-27 2023-02-01 デヴェラ セラピューティクス インコーポレイテッド 造血幹および前駆細胞を培養するための組成物および方法
JP7328729B2 (ja) * 2020-03-31 2023-08-17 Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 細胞の保存方法
WO2022005462A1 (en) * 2020-06-30 2022-01-06 Tr1X, Inc. Poly-donor cd4+ t cells expressing il-10 and uses thereof
CN114187965A (zh) * 2021-12-09 2022-03-15 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种人骨髓造血干/祖细胞的单细胞转录组图谱及构建方法
US20250135039A1 (en) 2022-02-07 2025-05-01 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5856441A (en) 1991-05-03 1999-01-05 Yale University Serrate fragments and derivatives
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5869282A (en) 1991-12-11 1999-02-09 Imperial Cancer Research Technology, Ltd. Nucleotide and protein sequences of the serrate gene and methods based thereon
WO1993012141A1 (en) 1991-12-11 1993-06-24 Yale University Nucleotide and protein sequences of the serrate gene and methods based thereon
DK0861261T3 (da) 1995-06-28 2009-12-14 Imp Cancer Res Tech Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
WO2002059285A1 (en) * 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
AU2003219966A1 (en) * 2002-03-05 2003-09-22 Daniel D. Richard Dual blood donation plus method
NZ542127A (en) * 2003-02-13 2008-04-30 Anthrogenesis Corp Use of umbilical cord blood to treat individuals having a disease, disorder or condition
JP2005102656A (ja) * 2003-10-02 2005-04-21 Toray Ind Inc 細胞培養器具およびそれを用いた細胞製剤の製造方法
KR20070002067A (ko) * 2004-03-26 2007-01-04 셀진 코포레이션 줄기 세포 은행의 제공 시스템 및 제공 방법
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
EP2626415A3 (en) * 2004-10-25 2014-04-16 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
KR20080027295A (ko) * 2005-06-02 2008-03-26 스템사이트, 인코포레이티드 혈장-제거되고, 적혈구-비제거된 제대혈 조성물 및 사용방법
AU2007214468B2 (en) 2006-02-14 2013-04-04 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3741842A4 (en) * 2018-09-27 2021-04-21 TERUMO Kabushiki Kaisha CELL CRYOPRESERVATION METHOD

Also Published As

Publication number Publication date
US20190298778A1 (en) 2019-10-03
JP2019141050A (ja) 2019-08-29
JP6853081B2 (ja) 2021-03-31
EP3590520B1 (en) 2021-12-29
JP2017141260A (ja) 2017-08-17
CA2795627C (en) 2023-03-14
JP2013523841A (ja) 2013-06-17
JP6998911B2 (ja) 2022-02-04
US20130095079A1 (en) 2013-04-18
JP2021105045A (ja) 2021-07-26
CA2795627A1 (en) 2011-10-13
US20190298777A1 (en) 2019-10-03
EP3590520A1 (en) 2020-01-08
EP3097917A1 (en) 2016-11-30
EP2555782A1 (en) 2013-02-13
EP3097917B1 (en) 2019-08-14
US20180085406A1 (en) 2018-03-29
WO2011127470A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
JP6998911B2 (ja) Ｈｌａの適合なしに造血機能を提供するための組成物
JP7041179B2 (ja) 造血機能を提供するための組成物および方法
WO1989004168A1 (en) Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US20220218759A1 (en) Compositions and methods for improving treatment outcomes for patients having hematological malignancies using an expanded stem cell product
HK1231737A1 (en) Compositions and methods for providing hematopoietic function without hla matching
HK1231737B (en) Compositions and methods for providing hematopoietic function without hla matching
HK1231736B (en) Compositions and methods for providing hematopoietic function
HK1231736A1 (en) Compositions and methods for providing hematopoietic function

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170322

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20170322

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170329

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20170404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170621

R150 Certificate of patent or registration of utility model

Ref document number: 6165627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250